Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers

Summary

Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic profile with participation of adult volunteers

Timeline

Start

2023-10

Primary completion

2024-12

Completion

2024-12

Publications

• Shuliakova IV, Grousova DM, Iliukhina AA, Dzharullaeva AS, Lubenets NL, Ordzhonikidze MK, Izhaeva FM, Erokhova AS, Zorkov ID, Azizyan VV, Boeva ZD, Reshetnikov DA, Ermolova IA, Lega VA, Kovyrshina AV, Bukhtin KM, Romanova LP, Alekseeva EI, Borzakova SN, Rachina SA, Rusanova MG, Ozharovskaia TA, Popova O, Zrelkin DI, Zubkova OV, Tukhvatulin AI, Tukhvatulina NM, Shcheblyakov DV, Favorskaya IA, Esmagambetov IB, Karpov AP, Semikhin AS, Pochtovyi AA, Naroditskiy BS, Gushchin VA, Gintsburg AL, Logunov DY. Sputnik V update: safety and neutralizing antibodies in healthy adults and adolescents. Front Immunol. 2026 Mar 26;17:1736771. doi: 10.3389/fimmu.2026.1736771. eCollection 2026.

Drugs

Indications